Zana Showcases Voice-Biomarker Innovation at ESC Digital & AI Summit 2025

Zana, a pioneer in AI-driven voice biomarkers and digital health, was selected to present its latest advancements at the European Society of Cardiology (ESC) Digital & AI Summit 2025, one of the most influential forums shaping the future of cardiovascular care. As a leading authority in cardiology, ESC plays a pivotal role in defining clinical standards, accelerating digital transformation, and bringing together experts across medicine, technology, and research. Being selected to present at this summit underscores the relevance and potential impact of Zana’s technology in the next era of digital cardiology.

At the Summit, Zana’s CEO and Co-Founder, Dr.-Ing. Julia Hoxha, presented on the Digital Stage, highlighting the company’s breakthrough VOICE-BIOME platform for AI-based patient voice analysis and early detection of cardiovascular deterioration. Zana also showcased its technology in the Technology & Innovation Demo Room, giving clinicians, researchers, and industry leaders the opportunity to experience real-time voice biomarker insights.

Attendees expressed strong interest, leading to engaging conversations and opening new pathways for further deployments and international traction. Adding to the momentum, Zana was also featured on ESC TV — a curated selection highlighting innovative solutions with high potential impact on cardiovascular care. “Being recognized at the ESC is a powerful validation of our mission,” said Dr.-Ing. Julia Hoxha. “The level of engagement and enthusiasm we saw confirms the growing potential for voice-based biomarkers as a new dimension of precision cardiology.”

As AI and digital tools continue to reshape cardiovascular medicine, Zana remains committed to advancing clinically meaningful innovation and collaborating with global partners to unlock new insights from the human voice.